Sanofi Enters Global Collaboration with ScionxBio for Long-Acting mRNA Therapeutics

Key Facts

1ScionxBio announced a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended-exposure mRNA therapeutics.

ScionxBio announced a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended-exposure mRNA therapeutics. Business Wire reported that the partnership aims to leverage ScionxBio's preclinical-stage xRNA platform to create treatments with an extended durability profile for commercial use.

SNY closed at $39.57 on October 19, 2026, with the stock trading between a day low of $39.51 and a high of $40.11 during that session. This strategic alliance is expected to validate ScionxBio's technology platform while expanding Sanofi's research pipeline in advanced genetic therapeutics.